Skip to Content
Morningstar

Canopy Growth Corp WEED

Morningstar Rating
Unlock
Stock XTSE Rating as of
CAD 10.79 −0.12 (1.10%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

First Pillar of Germany's Cannabis Legalization Begins April 1; Legal Sales to Come Later

Kristoffer Inton

The Bundestag, the lower house of Germany’s legislature, passed a cannabis bill last month that would allow possession of up to 25 grams and home-growing of up to three plants. The law will become effective April 1 as planned after the Bundesrat, the upper house, voted not to send it to mediation committee on March 22. The law expands on July 1 to allow nonprofit cannabis grow clubs of up to 500 members and 50 grams per member.

Read Full Report

Price vs Fair Value

View History
WEED is trading at a 19% premium.
Price
CAD 10.79
Fair Value
CAD 4.80
Uncertainty
Extreme
1-Star Price
CAD 37.40
5-Star Price
CAD 1.47
Economic Moat
Rnk
Capital Allocation
Dvdw

Bulls Say, Bears Say

Bulls

Canopy Growth’s plans to create Canopy USA to strengthen its competitive position before U.S. federal legalization.

Bears

While Canopy waits for U.S. federal legalization to enter the THC market there, U.S. multistate operators continue to grow bigger and become more competitive.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if WEED is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CAD 10.91
Day Range
CAD 10.50–11.45
52-Week Range
CAD 3.74–26.00
Bid/Ask
CAD 10.82 / CAD 10.82
Market Cap
CAD 983.13 Mil
Volume/Avg
2.2 Mil / 3.1 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.35
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,621
Website
https://www.canopygrowth.com

Competitors

Valuation

View More
Metric
WEED
CURLF
TLRY
Price/Earnings (Normalized)
 ———
Price/Book Value
 1.643.370.40
Price/Sales
 2.352.591.65
Price/Cash Flow
 —61.12—
Price/Earnings
WEED
CURLF
TLRY

Financial Strength

Metric
WEED
CURLF
TLRY
Quick Ratio
 1.130.310.96
Current Ratio
 1.790.851.92
Interest Coverage
 −9.27−0.24−4.39
Quick Ratio
WEED
CURLF
TLRY

Profitability

Metric
WEED
CURLF
TLRY
Return on Assets (Normalized)
 −23.44%−3.72%−13.42%
Return on Equity (Normalized)
 −57.88%−10.45%−17.13%
Return on Invested Capital (Normalized)
 −20.86%−2.20%−14.23%
Return on Assets
WEED
CURLF
TLRY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ZTS
Zoetis Inc Class ACdnfzhylrsKgmr$70.0 Bil
MKKGY
Merck KGaA ADRJmnbtxspKfkrwnx$68.4 Bil
HLN
Haleon PLC ADRHptnmmgwTgzm$37.0 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRDxsrkhvTkq$14.5 Bil
VTRS
Viatris IncJkxpyyqbPmpv$13.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRLzkkrjrDsc$12.0 Bil
CTLT
Catalent IncCzqtbpbtHgnqj$10.1 Bil
PRGO
Perrigo Co PLCLtwtvrjsWxg$4.1 Bil
CURLF
Curaleaf Holdings IncZxvmwjrccHfpb$3.6 Bil
PBH
Prestige Consumer Healthcare IncBcphmwdyTrmnfx$3.5 Bil

Sponsor Center